KRAS Oncogene Connect
  • Saved

5yr

Looks like a great webinar!
/>

Clinical Education Center

Clinical Education Center

Source : https://education.questdiagnostics.com/events/247?utm_medium=email&utm_source=eloqua

  • Saved

5yr

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Source : https://jamanetwork.com/journals/jamaoncology/article-abstract/2778198

  • 5yr
    Key Points • Novel study examining the correlation between KRAS status with outcomes following ICI monotherapy compared with that of chemoimmunotherapy in patients with PD-L1 of 50% or greater. • KRAS variants in NSCLC Show More
  • Saved

5yr

Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation - PubMed

Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33824136/

1 Massachusetts General Hospital. 2 Medical Oncology, Massachusetts General Hospital. 3 Department of Medicine, Massachusetts General Hospital. 4 Cancer Center, Massachusetts General Hospital. 5 Massachusetts General Hospital Cancer Center. 6...

  • Saved

5yr

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer

Source : https://www.nature.com/articles/s42003-021-01897-6

Maroni, Bassal, Krishnan et al. characterise human non-small cell lung cancer (NSCLC) carrying Kras-mutations by single-cell RNA sequencing. They identify a tumour-specific population that is conserved in mice and responds...

  • Saved

5yr

In a new study published online today in JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated with immunotherapy alone, compared to patients without this mutation.

Immunotherapy Alone Extended Life for Metastatic Lung Cancer Patients with KRAS Mutation - Penn Medicine

Immunotherapy Alone Extended Life for Metastatic Lung Cancer Patients with KRAS Mutation - Penn Medicine

Source : https://www.pennmedicine.org/news/news-releases/2021/april/immunotherapy-alone-extended-life-for-metastatic-lung-cancer-patients-with-kras-mutation

Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research...